Further studies revealed an association between the FA2H expression level and tumor growth in different cancers, e.g., breast cancers, prostate cancer, gastric cancer and colorectal cancer: a low FA2H expression was associated with a reduced (disease-free) survival [136], reduced sensitivity against chemotherapeutic drugs [137] and, in general, a poor prognosis [138,139,140]. This evidence concerns the gene FA2H and breast carcinoma.